Skip Navigation
Menu

Hyeongsu PARK Foreign Attorney

Hyeongsu PARK  Foreign Attorney
Hyeongsu PARK  Foreign Attorney

Hyeongsu PARK Foreign Attorney

T.+82-2-6488-4186F.+82-2-2122-3800E.hyeongsu.park@kimchang.com

Areas of Expertise

Overview

Hyeongsu Park advises clients on patent prosecution, patent licensing, opinion work, IP due diligence, patent strategies and litigation. With his background in biomedical engineering and molecular biology, he assists various clients including those in pharmaceutical, medical device and biotech industries.

Mr. Park received his J.D. from Harvard Law School. While in law school, he served as an editor and member of the Submissions Committee for the Harvard Journal of Law & Technology. He was also a student intern at the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School.

Prior to his legal education, Mr. Park earned his Bachelor's degree in Biological Engineering from Cornell University. He conducted research on a RNA-guided genome engineering (CRISPR/Cas9) system and a DNA-based drug delivery system.

Profile

Experience

Kim & Chang (2018, 2021-Current) 

Researcher, Bioinfra Life Science, Inc. (2018-2021) 

Knobbe, Martens, Olson & Bear LLP (2015-2017)

Representative ActivitiesView All

Publications/Activities
    • Inventive Step Standard of Korean Patent Law in Relation to Pharmaceutical Invention, 17(3) L. & Tech. 50 (2021)
    • Determining Punitive Damages for Patent Infringement - Intentional Infringement and Statutory Factors Affecting Punitive Damages, 16(2) L. & Tech. 87 (2020) 
    • Artificial Intelligence and Patent-Eligible Subject Matter Under Korean Patent Law, 15(5) L. & Tech. 18 (2019) 
    • The Legal Battle Around CRISPR Gene-Editing Technology and Its Implications, 36 Biotech. L. Rep. 39 (2017) 
    • What SCOTUS's Refusal To Review Cases on Patent-Eligible Subject Means, MedCity News (January 2017) 
    • Ten Strategies for Aggressively Building a Patent Portfolio, Medical Device and Diagnostics Industry (MD+DI) (November 2016) 
    • The Defend Trade Secrets Act's Implications for Medtech, Medical Device and Diagnostic Industry (MD+DI) (June 2016) 
    • Draft Guideline for the Revised De Novo Classification Process, Harv. J.L. & Tech. Dig. (June 2016) 
    • Taxpayer Data Disclosure for Academic Use in South Korea, 79 Tax Notes Int'l 955 (2015) (Co-authored with Yunjung Song) 
    • Written Description Problems of the Monoclonal Antibody Patents after Centocor v. Abbott, Harv. J.L. & Tech. Dig. (March 2014)

Education

Graduate School of Law, Seoul National University (Completed Coursework, LL.D., 2021) 

Harvard Law School (J.D., 2015) 

Graduate School of Arts and Sciences, Harvard University (Ph.D. Candidate, Molecular Biology, 2013-2014)

Cornell University (B.S., Biological Engineering, summa cum laude, Banner Bearer, 2010)

Qualifications

Admitted to bar, California, 2016 

Admitted to patent bar (limited recognition), U.S. Patent and Trademark Office, 2016

Languages

English and Korean

Insights

EXPERTISE

Close

EXPERTISE

Close

Share

Share
  

Hyeongsu PARK
Foreign Attorney


T. +82-2-6488-4186      
F. +82-2-2122-3800
     


  




Hyeongsu Park advises clients on patent prosecution, patent licensing, opinion work, IP due diligence, patent strategies and litigation. With his background in biomedical engineering and molecular biology, he assists various clients including those in pharmaceutical, medical device and biotech industries.

Mr. Park received his J.D. from Harvard Law School. While in law school, he served as an editor and member of the Submissions Committee for the Harvard Journal of Law & Technology. He was also a student intern at the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School.

Prior to his legal education, Mr. Park earned his Bachelor's degree in Biological Engineering from Cornell University. He conducted research on a RNA-guided genome engineering (CRISPR/Cas9) system and a DNA-based drug delivery system.






    Kim & Chang (2018, 2021-Current) 

    Researcher, Bioinfra Life Science, Inc. (2018-2021) 

    Knobbe, Martens, Olson & Bear LLP (2015-2017)






Publications/Activities

  •   Inventive Step Standard of Korean Patent Law in Relation to Pharmaceutical Invention, 17(3) L. & Tech. 50 (2021)
  •   Determining Punitive Damages for Patent Infringement - Intentional Infringement and Statutory Factors Affecting Punitive Damages, 16(2) L. & Tech. 87 (2020) 
  •   Artificial Intelligence and Patent-Eligible Subject Matter Under Korean Patent Law, 15(5) L. & Tech. 18 (2019) 
  •   The Legal Battle Around CRISPR Gene-Editing Technology and Its Implications, 36 Biotech. L. Rep. 39 (2017) 
  •   What SCOTUS's Refusal To Review Cases on Patent-Eligible Subject Means, MedCity News (January 2017) 
  •   Ten Strategies for Aggressively Building a Patent Portfolio, Medical Device and Diagnostics Industry (MD+DI) (November 2016) 
  •   The Defend Trade Secrets Act's Implications for Medtech, Medical Device and Diagnostic Industry (MD+DI) (June 2016) 
  •   Draft Guideline for the Revised De Novo Classification Process, Harv. J.L. & Tech. Dig. (June 2016) 
  •   Taxpayer Data Disclosure for Academic Use in South Korea, 79 Tax Notes Int'l 955 (2015) (Co-authored with Yunjung Song) 
  •   Written Description Problems of the Monoclonal Antibody Patents after Centocor v. Abbott, Harv. J.L. & Tech. Dig. (March 2014)





Education

    Graduate School of Law, Seoul National University (Completed Coursework, LL.D., 2021) 

    Harvard Law School (J.D., 2015) 

    Graduate School of Arts and Sciences, Harvard University (Ph.D. Candidate, Molecular Biology, 2013-2014)

    Cornell University (B.S., Biological Engineering, summa cum laude, Banner Bearer, 2010)


Qualifications

    Admitted to bar, California, 2016 

    Admitted to patent bar (limited recognition), U.S. Patent and Trademark Office, 2016


Languages
  •    English and Korean





Patent ,  Intellectual Property ,  Intellectual Property Litigation ,  Licensing & IP Transactions ,  IP Counseling & Strategy ,  Life Sciences and Healthcare ,  Pharmaceuticals (IP) ,  Healthcare & Medical Devices (IP) ,  Biotechnology & Life Sciences ,  Chemicals ,  Trade Secret & Corporate Information Protection ,  Privacy & Data Security ,  Mergers & Acquisitions ,  US ,  Economic Sanctions